NHERF1/EBP50 in breast cancer: Clinical perspectives

Breast Care

Volumn 5, Issue 2, 2010, Pages 86-90

  Bellizzi, Antonia ^a   Malfettone, Andrea ^a   Cardone, Rosa A ^b   Mangia, Anita ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Breast cancer; HER2 neu; NHERF1 EBP50

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; SODIUM PROTON EXCHANGE PROTEIN 1;

BINDING AFFINITY; BREAST CANCER; CANCER GRADING; GENE LOCUS; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR VOLUME;

EID: 77952847857     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000298962     Document Type: Review

References (38)

1. Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, Halberg F, Somerfield MR, Davidson NE; American Society of Clinical Oncology: American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006;24:5091-5097.
2. Nourry C, Grant SG, Borg JP: PDZ domain proteins: plug and play! Sci STKE 2003;2003:RE7.
3. Brône B, Eggermont J: PDZ proteins retain and regulate membrane transporters in polarized epithelial cell membranes. Am J Physiol Cell Physiol 2005;288:C20-29.
4. Weinman EJ, Hall RA, Friedman PA, Liu-Chen LY, Shenolikar S: The association of NHERF adaptor proteins with g protein-coupled receptors and receptor tyrosine kinases. Annu Rev Physiol 2006; 68:491-505.
5. Song J, Bai J, Yang W, Gabrielson EW, Chan DW, Zhang Z: Expression and clinicopathological significance of oestrogen-responsive ezrin-radixinmoesin- binding phosphoprotein 50 in breast cancer. Histopathology 2007;51:40-53. (Pubitemid 46976376)
6. Cardone RA, Bellizzi A, Busco G, Weinman EJ, Dell'Aquila ME, Casavola V, Azzariti A, Mangia A, Paradiso A, Reshkin SJ: The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells. Mol Biol Cell 2007;18:1768-1780.
7. Reczek D, Berryman M, Bretscher A: Identification of EBP50: a PDZ-containing phosphoprotein that associates with members of the ezrin-radixinmoesin family. J Cell Biol 1997;139:169-179.
8. Stemmer-Rachamimov AO, Wiederhold T, Nielsen GP, James M, Pinney-Michalowski D, Roy JE, Cohen WA, Ramesh V, Louis DN: NHE-RF, a merlin-interacting protein, is primarily expressed in luminal epithelia, proliferative endometrium, and estrogen receptor-positive breast carcinomas. Am J Pathol 2001;158:57-62.
9. Fouassier L, Duan CY, Feranchak AP, Yun CH, Sutherland E, Simon F, Fitz JG, Doctor RB: Ezrinradixin- moesin-binding phosphoprotein 50 is expressed at the apical membrane of rat liver epithelia. Hepatology 2001;33:166-176.
10. Weinman EJ, Steplock D, Wang Y, Shenolikar S: Characterization of a protein cofactor that mediates protein kinase A regulation of the renal brush border membrane Na(+)-H+ exchanger. J Clin Invest 1995;95:2143-2149.
11. Dai JL, Wang L, Sahin AA, Broemeling LD, Schutte M, Pan Y: NHERF (Na+/H+ exchanger regulatory factor) gene mutations in human breast cancer. Oncogene 2004;23:8681-8687.
12. Plummer SJ, Adams L, Simmons JA, Casey G: Localization of a growth suppressor activity in MCF7 breast cancer cells to chromosome 17q24-q25. Oncogene 1997;14:2339-2345.
13. Orsetti B, Courjal F, Cuny M, Rodriguez C, Theillet C: 17q21-q25 aberrations in breast cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification. Oncogene 1999;18: 6262-6270.
14. Presneau N, Dewar K, Forgetta V, Provencher D, Mes-Masson AM, Tonin PN: Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2. Mol Carcinog 2005;43:141-154.
15. Shibata T, Chuma M, Kokubu A, Sakamoto M, Hirohashi S: EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma. Hepatology 2003;38:178-186.
16. Fraenzer JT, Pan H, Minimo L Jr, Smith GM, Knauer D, Hung G: Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol 2003;23:1493-1500.
17. Voltz JW, Weinman EJ, Shenolikar S: Expanding the role of NHERF, a PDZ-domain containing protein adapter, to growth regulation. Oncogene 2001;20:6309-6314.
18. Schindelmann S, Windisch J, Grundmann R, Kreienberg R, Zeillinger R, Deissler H: Expression profiling of mammary carcinoma cell lines: correlation of in vitro invasiveness with expression of CD24. Tumor Biol 2002;23:139-145.
19. Mangia A, Chiriatti A, Bellizzi A, Malfettone A, Stea B, Zito FA, Reshkin SJ, Simone G, Paradiso A: Biological role of NHERF1 protein expression in breast cancer. Histopathology 2009;55:600-608.
20. Georgescu MM, Morales FC, Molina JR, Hayashi Y: Roles of NHERF1/EBP50 in cancer. Curr Mol Med 2008;8:459-468.
21. Moriya T, Silverberg SG: Intraductal carcinoma (ductal carcinoma in situ) of the breast. A comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma. Cancer 1994;74:2972-2978.
22. Inouye T, Inokuchi M, Shimizu K, Abe K: Interstitial vascular reaction of naturally occurring mammary adenocarcinoma in old C3H/HeJ female mice. Jikken Dobutsu 1984;33:151-157.
23. Favaro E, Nardo G, Persano L, Masiero M, Moserle L, Zamarchi R, Rossi E, Esposito G, Plebani M, Sattler U, Mann T, Mueller-Klieser W, Ciminale V, Amadori A, Indraccolo S: Hypoxia inducible factor-1alpha inactivation unveils a link between tumor cell metabolism and hypoxia-induced cell death. Am J Pathol 2008;173:1186-1201.
24. Covello KL, Simon MC: HIFs, hypoxia, and vascular development. Curr Top Dev Biol 2004;62:37-54.
25. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW: Overexpression of hypoxia- inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59: 5830-5835.
26. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM: MRI of the tumor microenvironment. J Magn Reson Imaging 2002;16:430-450.
27. Cardone RA, Casavola V, Reshkin SJ: The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer 2005;5:786-795.
28. Ediger TR, Kraus WL, Weinman EJ, Katzenellenbogen BS: Estrogen receptor regulation of the Na+/H+ exchange regulatory factor. Endocrinology 1999;140:2976-2982.
29. Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA, Katzenellenbogen BS: Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol Cell Endocrinol 2003;206:13-22.
30. Hermanek P, Sobin LH (eds): UICC TNM: Classification of Malignant Tumours, 4th ed. New York, John Wiley and Sons, 1988.
31. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002;41:154-161.
32. Bereznaya NM, Kirnasovskaya EA, Vinnichuk YD, Belova OB, Lukyanova NY: Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors. Exp Oncol 2008;30:295-299.
33. Standish LJ, Sweet ES, Novack J, Wenner CA, Bridge C, Nelson A, Martzen M, Torkelson C: Breast cancer and the immune system. J Soc Integr Oncol 2008;6:158-168.
34. Maudsley S, Zamah AM, Rahman N, Blitzer JT, Luttrell LM, Lefkowitz RJ, Hall RA: Plateletderived growth factor receptor association with Na(+)/H(+) exchanger regulatory factor potentiates receptor activity. Mol Cell Biol 2000;20:8352-8363.
35. Lazar CS, Cresson CM, Lauffenburger DA, Gill GN: The Na+/H+ exchanger regulatory factor stabilizes epidermal growth factor receptors at the cell surface. Mol Biol Cell 2004;15:5470-5480.
36. Cao TT, Deacon HW, Reczek D, Bretscher A, von Zastrow M: A kinase-regulated PDZ-domain interaction controls endocytic sorting of the beta2- adrenergic receptor. Nature 1999;401:286-290.
37. Weinman EJ, Steplock D, Wade JB, Shenolikar S: Ezrin binding domain-deficient NHERF attenuates cAMP-mediated inhibition of Na(+)/H(+) exchange in OK cells. Am J Physiol Renal Physiol 2001;281:F374-380.
38. Pan Y, Weinman EJ, Dai JL: Na+/H+ exchanger regulatory factor 1 inhibits platelet-derived growth factor signalling in breast cancer cells. Breast Cancer Res 2008;10:R5.